生物活性 | |||
---|---|---|---|
描述 | Darovasertib, also known as LXS196, is an effective, selective, orally active PKC inhibitor, with IC50 values of 1.9 nM for PKCα, 0.4 nM for PKCθ, and 3.1 μM for GSK3β. Darovasertib holds potential for research in uveal melanoma[1][2]. Upon oral administration, Darovasertib binds to and inhibits PKC, thereby preventing the activation of PKC-mediated signaling pathways. This may result in cell cycle arrest and the induction of apoptosis in sensitive tumor cells[1]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.12mL 0.42mL 0.21mL |
10.58mL 2.12mL 1.06mL |
21.17mL 4.23mL 2.12mL |
参考文献 |
---|